Zymera, Inc.
Zymera, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Zymera, Inc..
Zymera, Inc. is a company.
Key people at Zymera, Inc..
Zymera, Inc. is a privately held nanobiotechnology company focused on developing self-illuminating quantum dot technologies for advanced imaging and biosensing applications.[2][5] It builds products combining Bioluminescence Resonance Energy Transfer (BRET) with quantum dots to enable non-toxic, autofluorescence-free imaging deeper in tissues, serving life science researchers, medical diagnostics, and biotech firms by solving problems in in vivo imaging, biomarker discovery, cell tracking, and fluid flow tracing.[2][5][8] The company has secured government grants like an STTR Phase I for non-toxic nanoparticles and a licensing deal with Life Technologies for Qdot nanocrystals, indicating early validation but limited public evidence of current growth momentum.[5][6][8]
Note: Search results reveal potential confusion with similarly named entities like Zymera Solutions LLC (a tech consulting firm)[1][7] and ZYMERA LTD (a new UK retail company),[4] but Zymera, Inc. specifically aligns with the nanobiotech profile in California.[2][3]
Zymera, Inc. emerged in the nanobiotechnology space, with early activity tied to U.S. government funding, including a Small Business Technology Transfer (STTR) Phase I grant for "Non-Toxic Nanoparticles for BRET-Based Molecular Imaging."[6] Located in Portola Valley, California, it positioned itself as a cutting-edge medical laboratory pioneering self-illuminating red to near-infrared (NIR) emitting technologies.[2][3] A pivotal moment came around 2011 when Life Technologies licensed its quantum dots IP to Zymera, enabling combination with Zymera's BRET tech for new products—no specific founders are named in available records, and recent public traction appears dormant.[5][8]
Zymera rides the wave of advanced bioimaging trends, where demand for non-invasive, high-resolution in vivo tools accelerates due to rising needs in personalized medicine, oncology, and drug development.[5] Timing aligns with early 2010s biotech innovation spurred by quantum dot advancements and government grants like STTR, amid market forces favoring deeper tissue visualization amid limitations of traditional fluorescence methods.[2][6] It influences the ecosystem by pushing BRET-quantum dot hybrids, potentially lowering barriers for multiplexed imaging in preclinical research, though its impact remains niche given sparse recent activity.[5][8]
Zymera's path forward hinges on commercializing its BRET-quantum dot platform amid evolving nanobiotech demands for real-time, non-toxic imaging in therapeutics and diagnostics. Trends like AI-enhanced imaging and CRISPR-related tracking could revive momentum if the company reemerges from apparent dormancy, evolving its influence through partnerships or acquisitions in the growing $10B+ bioimaging market. Watch for grant renewals or IP licensing as signals of renewed traction, building on its foundational tech edge to claim a slice of precision medicine's expansion.[2][5][6]
Key people at Zymera, Inc..